StockMarketWire.com - Regenerative medical devices company Tissue Regenix said it had appointed Daniel Lee as chief executive.

Lee was currently the head of the company's US operations, a role he'd commenced in January 2019.

Previous to that, he was CEO of Scaffold Biologics and Aperion Biologics.


At 8:50am: [LON:TRX] Tissue Regenix Group PLC share price was 0p at 0.41p



Story provided by StockMarketWire.com